Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales.
Company Growth (employees)
Type
Private
HQ
Ingelheim Am Rhein, DE
Founded
1885
Size (employees)
34,724 (est)
Boehringer Ingelheim was founded in 1885 and is headquartered in Ingelheim am Rhein, DE

Boehringer Ingelheim Office Locations

Boehringer Ingelheim has an office in Ingelheim am Rhein
Ingelheim am Rhein, DE (HQ)
173 Binger Str.

Boehringer Ingelheim Data and Metrics

Summary Metrics

Founding Date

1885

Boehringer Ingelheim Median Salaries

Source: 39 public H-1B filings from Boehringer Ingelheim

Traffic Overview of Boehringer Ingelheim

Boehringer Ingelheim Online and Social Media Presence

Boehringer Ingelheim News and Updates

Strong Medicine: Where Big Pharma Is Placing Bets In Digital Health In One Timeline

Digital health startups raised over $6B in equity financing in 2016, and investment into the sector is showing no signs of slowing down. Traditionally, investors in this space have been VCs such as Rock Health and Khosla Ventures or corporate … Continued

Big Tech And Pharma Bet On Cancer Therapy Startups: Celgene, Novartis, Pfizer, and Google’s Investments

Corporate interest in life-science startups developing cancer therapies has been increasing over the years. Corporate-backed deals are up from around 30 in 2012 to nearly 50 so far this year (as of 10/26/16). Apart from big pharma companies like Novartis, … Continued

EU mergers and takeovers (July 19)

BRUSSELS, July 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Biotech giant bows to takeover pressure and opens books to suitors

US biotech giant Medivation has signed confidentiality agreements with several suitors, including Sanofi SA, paving the way for a potential a $10bn (£7.7bn) sale. Speculation over the possibility of a takeover has followed the company for months. Pharma giants Pfizer and Celgene have also sign…
Show more

Boehringer Ingelheim Company Life and Culture

You may also be interested in